Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO dosing schedule trial in severe aplastic anemia with thrombocytopenia
ChiCTR1800019669Phase 4Not yet recruiting
- Sponsor
- Peking University Institute of Hematology
- Start
- Jan 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin in aplastic anemia and Thrombocytopenia (2 arms), sponsored by Peking University Institute of Hematology. Primary endpoint: Platelet transfusion independence rate at 3 months. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
aplastic anemiaThrombocytopenia
Beyond the preview
Go deeper on ChiCTR1800019669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019669.